A century-in-the-making pandemic was on its way and we, in the live marketing industry – like everyone – were pretty much ...

It is incumbent not only on people to have the willingness to learn, but also on pharmaceutical and scientific industries to ...

Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of ...

However, significant barriers stand in the way of realising this promise on a worldwide scale, from manufacturing costs and ...

The alliance will pair EVERSANA's NAVLIN platform, which provides data and information on global pricing and market access, ...

The European Medicines Agency (EMA) has joined the hordes of users abandoning Elon Musk's X.com (formerly Twitter) and will ...

As recent advances in small molecules, ADCs, cell, and gene therapies poise novel precision therapies from the bench to the ...

Shares in 23andMe are currently trading at around $3.40, giving it a valuation of just under $82 million. The company went public via a merger with a special purpose acquisition company (SPAC) in 2021 ...

At JP Morgan Week 2025, pharmaphorum’s Jonah Comstock took a quick detour to Grove.AI’s San Francisco offices to talk to ...

As scientific discovery and technology advance, new opportunities arise and business priorities shift throughout the global ...

Chinese biotech Ascentage Pharma has taken the first US biotech initial public offering (IPO) of 2025 over the finish line, ...

The scale of the decline in Veru's shares despite the positive result may reflect the amplified expectations of investors for ...